Last reviewed · How we verify
50 mCi NYMO32
At a glance
| Generic name | 50 mCi NYMO32 |
|---|---|
| Sponsor | Zhengguo Chen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 50 mCi NYMO32 CI brief — competitive landscape report
- 50 mCi NYMO32 updates RSS · CI watch RSS
- Zhengguo Chen portfolio CI